GlassScriptPhysician profile
Sean P White
NPI 1912961764
$2,301.29
in general payments reported to CMS, 2019-2025
29 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $34.59 · 2021: $276 · 2022: $709 · 2023: $261 · 2024: $358 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.66 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Exeltis, USA INC. | $217.57 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $195.03 | 2024-2025 | Veozah |
| Amag Pharmaceuticals, INC. | $139.20 | 2019 | |
| Sumitomo Pharma America, INC. | $137.11 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $132.42 | 2021-2022 | |
| Pfizer INC. | $122.22 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $89.84 | 2021-2025 | |
| Avion Pharmaceuticals | $83.73 | 2021-2023 | Balcoltra |
| Duchesnay USA Incorporated | $64.07 | 2019 | |
| Boston Scientific Corporation | $56.88 | 2025 | General - Female Sui |
| Therapeuticsmd, INC. | $56.51 | 2022 | |
| Sage Therapeutics, LLC | $47.57 | 2024 | |
| Daiichi Sankyo INC. | $42.94 | 2019-2021 | |
| Medline Industries LP | $42.35 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $32.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.03 | 2021-2025 | Gardasil 9 |
| Ferring Pharmaceuticals INC. | $30.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.23 | 2019 | |
| Shield Therapeutics INC | $29.63 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $26.08 | 2022 | |
| Amgen INC. | $25.91 | 2019 | |
| Applied Medical Resources Corporation | $22.33 | 2023 | |
| Organon LLC | $18.12 | 2024 | |
| Novo Nordisk INC | $16.09 | 2023 | Wegovy |
| Minerva Surgical, INC | $14.20 | 2022 | |
| Ethicon US, LLC | $13.79 | 2019 | |
| Becton, Dickinson and Company | $13.77 | 2021 | |
| Lupin INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.